

PATENT

Docket No.: DEAV2003/0007 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Uwe Heinelt et. al.

Examiner: Stockton, Laura

Art Unit: 1626

Serial No.: 10/770,654

Filed: February 3, 2004

Certificate of Transmission

Title: N-Substituted (Benzoimidazol-2-yl)phenylamines
Process for Their Preparation,
Their Use as a Medicament or Diagnostic
and
Medicaments Containing Them

I hereby certify that this correspondence is being transmitted via EFS-Web to the Commissioner for Patents, Washington, D.C. 20231, on

January 5, 2007

Date of Transmission

Brian Pritchett Brian Pritchett
Signature

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Restriction/Election Requirement Under 35 U.S.C. § 121

Sir:

This is in response to the Office Action dated December 11, 2006, having a response due by January 11, 2006 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

PROVISIONAL ELECTION:


Applicants provisionally elect with traverse the invention Group I, claims 1-3, 12 and 13 drawn to products of formula 1 classified in class 548, subclass 304.4.

ELECTION OF A SUB-SPECIES AND A SINGLE DISCLOSED COMPOUND:

Applicants herein are required to elect a single disclosed species from the group comprising a member of the platform molecule as recited in claim 1. To this end,

Applicants provisionally elect with traverse the species (1H-Benzoimidazol-2-yl)(2,6-

dichlorophenyl)methylamine as disclosed in Example 2.



Please note that all of claims 1 to 3, 12 and 13 read on this elected subgeneric species as well as the single disclosed compound as provisionally elected herein.

Remarks

In the Office Action, the Examiner noted that claims 1 to 13 are subject to restriction. In particular, the Examiner has given a two-way restriction in accordance with 35 U.S.C. 121 as follows:

<i>Inventions</i>	<i>Classification</i>
Group I. Claims 1-3, 12 and 13 drawn to products of formula I.	548/304.4
Group II. Claims 4-11 drawn to methods of using the compounds of formula I.	514/388

As indicated above, through this response, Applicants provisionally elect invention Group I *with traverse*, namely, claims 1-3, 12 and 13 products drawn to products of a chemical compound defined by formula I. Additionally, as requested by the Examiner, Applicants have also provisionally elected with traverse a sub-generic species falling within the scope of Group I of formula I, wherein the species is (1H-Benzimidazol-2-yl)(2,6- dichlorophenyl)methylamine as disclosed in Example 2.